Cargando…
Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, rando...
Autores principales: | Wong, Martin C. S., Zhang, Lin, Ching, Jessica Y. L., Mak, Joyce W. Y., Huang, Junjie, Wang, Shilan, Mok, Chris K. P., Wong, Angie, Chiu, Oi-Lee, Fung, Yee-Ting, Cheong, Pui-Kuan, Tun, Hein-Min, Ng, Siew C., Chan, Francis K. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143994/ https://www.ncbi.nlm.nih.gov/pubmed/37111201 http://dx.doi.org/10.3390/nu15081982 |
Ejemplares similares
-
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines
por: Peng, Ye, et al.
Publicado: (2023) -
Gut microbiome signatures reflect different subtypes of irritable bowel syndrome
por: Su, Qi, et al.
Publicado: (2022) -
Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction
por: Zhang, Saisai, et al.
Publicado: (2022) -
The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?
por: Segal, Jonathan P., et al.
Publicado: (2020) -
Probiotics and COVID-19 – Authors' reply
por: Mak, Joyce W Y, et al.
Publicado: (2020)